U.S. Markets open in 8 hrs 44 mins

Endo’s Generic and International Segments Declined in Q1 2018

Kenneth Smith
Endo’s Generic and International Segments Declined in Q1 2018

Under Endo International’s (ENDP) established products, Percocet sales increased from $30.94 million in Q1 2017 to $31.97 million in Q1 2018. The increase was attributable to higher prices, partially offset by a decline in volume. Voltaren gel sales, on the other hand, decreased from $14.27 million in Q1 2017 to $11.32 million in Q1 2018 due to lower prices resulting from generic competition. Sales from other established products also decreased, from $64.48 million in Q1 2017 to $45.03 million in Q1 2018.